Clinical trial NCT05439746: A Study to Evaluate the Efficacy of Microlyte Matrix in the Management of Donor Site Wounds
Official title: Clinical Trial to Assess the Efficacy of Microlyte Matrix on the Healing of Surgically Created Partial Thickness Donor Site Wounds on Patients Requiring Split-thickness Skin Grafting
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Wounds and Injuries
Keywords: Donor
Skin Graft
Wound
Partial Thickness
Lead sponsor: Imbed Biosciences
Sponsor class: INDUSTRY
Collaborators: name: Arizona Burn Center, Maricopa Medical Center (Phoenix, AZ)
First posted: 2022-06-30
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A study to to evaluate the efficacy of Microlyte® Matrix by demonstrating its superiority to the standard of care in the healing of donor site wounds in patients requiring split-thickness grafting, as well as to assess the occurrence of donor site wound infection, allergic reaction, pain and itching, and scarring at 12 weeks, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS).

Detailed description: The proposed study is a randomized, controlled, open-label clinical trial to assess the efficacy in wound healing of the FDA 510k cleared Microlyte® Matrix (K153756) in surgically created partial thickness donor site wounds \> 100 cm2 in size on patients and harvested at 12/1000th inch requiring split-thickness skin grafting. Subjects are expected to be hospitalized as in-patients for approximately 7 days following initial donor site surgery. Study visits conducted after hospital discharge must be conducted as out-patient clinic visits.

Each wound will be divided into proximal and distal halves with one half randomized to receive Microlyte® Matrix. Kaltostat/Tegaderm will be used as the control. Thus, each patient is their own control removing the potential variability of the depth of donor site wounds between patients as a confounding factor.

Microlyte® Matrix is a FDA-cleared (K153756) antimicrobial dressing manufactured by Imbed Biosciences, Inc. (Madison, WI), which is an ISO 13485 certified/FDA QSR compliant facility. It is indicated for the management of partial and full thickness wounds including pressure ulcers, venous stasis ulcers, diabetic foot ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds.

Eligibility criteria: Inclusion Criteria:

1. Adult patients where creation of a donor site wound for any indication including chronic wound, burn wound, surgical/traumatic wound, and tumor excision.
2. Donor site wound with a surface area of greater than 100 cm2 is required.
3. At least 18 years of age
4. Provision of signed and dated informed consent form
5. Stated willingness to comply with all study procedures and availability for the duration of the study
6. Ability and willingness to adhere to the study intervention regimen and follow-up visits

Exclusion Criteria:

1. Age less than 18 years.
2. Vulnerable population.
3. Pregnant, lactating or nursing women.
4. Unable to provide consent.
5. Presumed unable to complete follow-up assessments.
6. Prior adverse reaction or sensitivity to silver.
7. Enrollment in another interventional trial using a systemic therapeutic within 30 days prior to enrollment for this study.
8. Presumed impairment of wound healing as with prescription drugs or medical diagnoses that have potential to impair wound healing at the discretion of clinical investigator, e.g., cancer, transplant status, autoimmune disease, severe malnutrition, etc.
9. Any diagnosis with concern for 30 Day mortality.

Primary outcomes:
measure: Percentage of donor site wound closure
timeFrame: Day 14 post-op
Secondary outcomes:
measure: Percentage of donor site wound closure
timeFrame: Day 7 post-op
measure: Durability of wound closure, assessed by percentage of wound closure
timeFrame: 12 weeks
measure: Pain, itching, and scarring, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS).
timeFrame: 12 weeks
measure: Signs of infection or allergic reactions, pain, and pruritus
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
References: